A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Part of paid clinical trials in Edison, New Jersey.
- Sponsor
- InduPro, Inc.
- Study ID
- NCT07602842
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Advanced Solid Tumor
- Cutaneous Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Metastatic Solid Tumor
- Non Squamous Non Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Anus
- Squamous Cell Carcinoma of the Cervix
- Squamous Cell Carcinoma of the Esophagus
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IDP-001 — DRUGIV infusion
Study Details
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- May 2026
- Primary completion
- Jun 30, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 132 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 1 Part 1 Dose EscalationParticipants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
- Experimental: Phase 1 Part 2 Indication SelectionParticipants with a single tumor indication will receive IDP-001 as IV infusion
Primary Outcome Measure
Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1 [ Time Frame: 3 weeks ]
Central Contacts
- InduPro Inc.617-798-1770
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Hackensack Meridian - John Theurer Cancer Center | Edison | New Jersey | 08837 |
Find similar trials in Edison, NJ
By condition
By specialty
By research site
Related Studies
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPHASE2 · Recruiting · ECOG-ACRIN Cancer Research Group · Birmingham, Alabama
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsPHASE1/PHASE2 · Recruiting · Daiichi Sankyo · Los Angeles, California